# Clinuvel Pharmaceuticals (CUVL) — Overview

CUVL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cuvl

## Price

Last close $5.06 on Oct 15, 2026. 52-week range $5.06 – $7.80.

## Company profile

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $94.0M |
| Revenue (quarter) | $94.0M |
| Revenue growth (year over year) | -1.05% |
| Gross profit (trailing twelve months) | $78.2M |
| Gross margin | 83.18% |
| Net income (trailing twelve months) | $33.9M |
| Net income (quarter) | $33.9M |
| Net income growth (year over year) | -6.24% |
| Net margin | 36.07% |
| Return on equity | 13.21% |
| EPS (trailing twelve months) | $0.68 |
| Book value per share | $0.00 |
| P/E (trailing twelve months) | 7.5 |
| Price to book | 0.9 |
| Debt to assets | 7.53% |
| Payout ratio | 0.00% |
| Dividend yield | 0.57% |

## Frequently Asked Questions

### Is Clinuvel Pharmaceuticals (CUVL) profitable?

Yes. Clinuvel Pharmaceuticals earned $33.9M in net income over the trailing twelve months, a net margin of 36.07%.

### How much revenue does Clinuvel Pharmaceuticals (CUVL) make?

Clinuvel Pharmaceuticals generated $94.0M in revenue over the trailing twelve months, down 1.05% year over year.

### What is CUVL's P/E ratio?

Clinuvel Pharmaceuticals trades at 7.5 times trailing twelve-month earnings, on an EPS of $0.68.

### How do I buy stock in Clinuvel Pharmaceuticals (CUVL)?

CUVL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).